BioMarin Pharmaceutical 미래 성장

Future 기준 확인 3/6

BioMarin Pharmaceutical (는) 각각 연간 27.1% 및 7.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 25.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11.9% 로 예상됩니다.

주요 정보

27.1%

수익 성장률

25.8%

EPS 성장률

Biotechs 수익 성장	27.7%
매출 성장률	7.6%
향후 자기자본 수익률	11.9%
애널리스트 커버리지	Good
마지막 업데이트	12 Dec 2024

최근 미래 성장 업데이트

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26

Recent updates

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Jun 01

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

May 15

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Apr 21

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Mar 30

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Feb 29

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Jan 19

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Jan 05

BioMarin redesigns organization, will lay off about 4% of its workforce

Oct 07

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

Sep 29

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

Sep 15

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

Aug 25

BioMarin may be an activist target after 13-F filings

Aug 15

BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth

Aug 03

BioMarin: More Growth

Jul 21

BioMarin's Solid Pipeline Bears The First Fruit

Jun 27

수익 및 매출 성장 예측

NasdaqGS:BMRN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	3,393	794	943	870	22
12/31/2025	3,098	585	792	804	27
12/31/2024	2,815	397	678	594	28
9/30/2024	2,753	322	311	415	N/A
6/30/2024	2,588	257	223	329	N/A
3/31/2024	2,472	205	173	280	N/A
12/31/2023	2,419	168	52	159	N/A
9/30/2023	2,311	147	25	139	N/A
6/30/2023	2,235	100	34	161	N/A
3/31/2023	2,173	72	15	147	N/A
12/31/2022	2,096	142	148	176	N/A
9/30/2022	2,008	84	151	180	N/A
6/30/2022	1,912	54	106	119	N/A
3/31/2022	1,880	39	134	146	N/A
12/31/2021	1,846	-64	185	305	N/A
9/30/2021	1,849	16	165	280	N/A
6/30/2021	1,917	837	155	269	N/A
3/31/2021	1,844	795	92	214	N/A
12/31/2020	1,860	854	15	85	N/A
9/30/2020	1,863	852	75	156	N/A
6/30/2020	1,847	122	58	140	N/A
3/31/2020	1,805	114	3	88	N/A
12/31/2019	1,704	-24	-90	48	N/A
9/30/2019	1,603	-43	-59	40	N/A
6/30/2019	1,533	-110	-112	17	N/A
3/31/2019	1,519	-90	-87	8	N/A
12/31/2018	1,491	-77	-74	20	N/A
9/30/2018	1,496	-125	-12	-15	N/A
6/30/2018	1,439	-125	N/A	-23	N/A
3/31/2018	1,383	-145	N/A	29	N/A
12/31/2017	1,314	-117	N/A	-9	N/A
9/30/2017	1,255	-156	N/A	-24	N/A
6/30/2017	1,201	-181	N/A	-72	N/A
3/31/2017	1,184	-563	N/A	-137	N/A
12/31/2016	1,117	-630	N/A	-228	N/A
9/30/2016	1,045	-471	N/A	-293	N/A
6/30/2016	974	-524	N/A	-286	N/A
3/31/2016	924	-187	N/A	-253	N/A
12/31/2015	890	-172	N/A	-219	N/A
9/30/2015	892	-310	N/A	-179	N/A
6/30/2015	859	-212	N/A	-185	N/A
3/31/2015	801	-163	N/A	-183	N/A
12/31/2014	749	-134	N/A	-70	N/A
9/30/2014	666	-126	N/A	-58	N/A
6/30/2014	627	-187	N/A	-59	N/A
3/31/2014	572	-175	N/A	-54	N/A
12/31/2013	548	-176	N/A	-57	N/A

애널리스트 미래 성장 예측

수입 대 저축률: BMRN 의 연간 예상 수익 증가율( 27.1% )이 saving rate( 2.6% 보다 높습니다. ).

수익 vs 시장: BMRN 의 연간 수익( 27.1% ) US 시장( 15.3% 보다 빠르게 성장할 것으로 예상됩니다. 15.3% 연간).

고성장 수익: BMRN 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: BMRN 의 수익(연간 7.6% ) US 시장( 9.1% 보다 느리게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: BMRN 의 수익(연간 7.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: BMRN 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 11.9 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/18 10:50
장 마감 주가	2024/12/18 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

BioMarin Pharmaceutical Inc. 59 애널리스트 중 28 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jack Allen	Baird
Ishan Majumdar	Baptista Research
Ying Huang	Barclays

BioMarin Pharmaceutical 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024

Price target decreased by 7.0% to US$104

Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027

Consensus EPS estimates increase by 10%

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates increase by 17%

Recent updates

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024

Price target decreased by 7.0% to US$104

BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia At 2024 International Skeletal Dysplasia Society Meeting

Investor sentiment deteriorates as stock falls 17%

Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

BioMarin Pharmaceutical Inc. Announces Management Changes

Consensus EPS estimates increase by 10%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Executive VP notifies of intention to sell stock

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

Director notifies of intention to sell stock

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2024 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 17%

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Insider recently sold US$3.0m worth of stock

Insider notifies of intention to sell stock

Biomarin Announces Board Changes, Effective May 20, 2024

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Full year 2023 earnings released: EPS: US$0.89 (vs US$0.76 in FY 2022)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Director notifies of intention to sell stock

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

Director notifies of intention to sell stock

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023

Executive VP notifies of intention to sell stock

Biomarin Pharmaceutical Inc. Announces CEO Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023

U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe

Executive VP recently sold US$984k worth of stock

Second quarter 2023 earnings: EPS exceeds analyst expectations

Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023

Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc

U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program

Chairman & CEO notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 13%

Independent Director notifies of intention to sell stock

Chairman & CEO notifies of intention to sell stock

Executive VP & Chief Legal Officer exercised options to buy US$148k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 32%

Chairman & CEO notifies of intention to sell stock

BioMarin Pharmaceutical Inc. to Report Q4, 2022 Results on Feb 27, 2023

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Executive VP of Finance & CFO exercised options and sold US$129k worth of stock

Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for Roctavian(Tm) in Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At 3-Year Analysis